Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies [Phase 1]
A Phase 1 clinical trial evaluates PRT2527 as a standalone therapy and in combination with zanubrutinib or venetoclax for relapsed/refractor…
-
CLINICAL_TRIALS trial_result · 2026-01-14Clinical Trial Update: Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance [Phase 2]
This Phase 2 trial evaluated upfront and maintenance obinutuzumab in mantle cell lymphoma treated with the DHAP regimen and MRD-driven maint…
-
CLINICAL_TRIALS trial_result · 2026-01-07Clinical Trial Update: Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma [Phase 2]
Phase 2 trial evaluating ultra-low-dose orbital radiation therapy for Stage I-IV indolent B-cell non-Hodgkin lymphoma and mantle cell lympho…
-
CLINICAL_TRIALS trial_result · 2025-12-30Clinical Trial Update: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) [Phase 1, Phase 2]
The Phase 1/Phase 2 trial of TQB3909 tablets for relapsed or refractory mantle cell lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-12-24Clinical Trial Update: Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients [Phase 1]
Phase 1 study assessing safety and tolerability of CD19x22 CAR T cells in adolescents and adults with relapsed/refractory B-cell non-Hodgkin…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-12-09Clinical Trial Update: Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) [NA]
Clinical trial update on adaptive bridging radiotherapy for relapsed/refractory B-cell lymphomas prior to CAR-T therapy; the study status is…
-
CLINICAL_TRIALS trial_result · 2025-12-08Clinical Trial Update: Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL [Phase 2]
Phase 2 trial assessing rituximab, bendamustine, and cytarabine followed by venetoclax in high-risk elderly patients with mantle cell lympho…
-
CLINICAL_TRIALS trial_result · 2025-12-02Clinical Trial Update: Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma [Phase 1, Phase 2]
Clinical trial update describing a multicenter, single-arm Phase I/II exploratory study to assess the safety and efficacy of a fully human B…
-
CLINICAL_TRIALS trial_result · 2025-11-26Clinical Trial Update: Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma [Phase 1]
This Phase 1 trial examined lenalidomide combined with blinatumomab for relapsed non-Hodgkin lymphoma across multiple subtypes and has compl…
-
CLINICAL_TRIALS trial_result · 2025-11-17Clinical Trial Update: Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) [Phase 2]
Phase 2 trial update for Brexucabtagene Autoleucel (KTE-X19) in relapsed/refractory mantle cell lymphoma (Cohort 3) indicates the study stat…
-
CLINICAL_TRIALS trial_result · 2025-11-10Clinical Trial Update: Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine [Phase 1]
A Phase 1 clinical trial evaluating a haploidentical bone marrow transplant using post-transplant cyclophosphamide and bendamustine has comp…
-
CLINICAL_TRIALS trial_result · 2025-11-03Clinical Trial Update: Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies [Phase 2]
Phase 2 trial evaluating nivolumab in patients with hematologic malignancies after CAR-T therapy; results have been posted with the study cu…
-
CLINICAL_TRIALS trial_result · 2025-10-21Clinical Trial Update: A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma [Phase 2]
A Phase 2 trial is evaluating the combination of acalabrutinib, venetoclax, and rituximab in treatment-naïve mantle cell lymphoma; the study…
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas [Phase 1]
Phase 1 study update for IKS03 in advanced B-cell non-Hodgkin lymphomas is currently recruiting across multiple subtypes including diffuse l…
-
CLINICAL_TRIALS trial_result · 2025-09-09Clinical Trial Update: Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma [Phase 1, Phase 2]
Update on a Phase 1/2 study evaluating BGB-11417 monotherapy in participants with relapsed or refractory Mantle Cell Lymphoma; the trial is …
-
CLINICAL_TRIALS trial_result · 2025-08-06Clinical Trial Update: Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma [Phase 2]
Phase 2 study results are posted for a Bendamustine, Obinutuzumab, and Venetoclax regimen in patients with untreated Mantle Cell Lymphoma.
-
CLINICAL_TRIALS trial_result · 2025-08-03Clinical Trial Update: Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies [Phase 1]
Phase 1 clinical trial update on genetically engineered CAR T cells (EGFRt/19-28z/IL-12) for relapsed or refractory CD19+ hematologic malign…
-
CLINICAL_TRIALS trial_result · 2025-08-01Clinical Trial Update: A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) [Phase 2]
Phase 2 trial comparing BeEAM and BEAM high-dose chemotherapy regimens before autologous stem cell transplantation in lymphoma patients; the…
-
CLINICAL_TRIALS trial_result · 2025-07-24Clinical Trial Update: A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients [Phase 1, Phase 2]
A Phase 1/2 trial evaluating the combination of obinutuzumab (GDC-0199) and ibrutinib in relapsed/refractory mantle cell lymphoma has comple…
-
CLINICAL_TRIALS trial_result · 2025-07-23Clinical Trial Update: Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma [Phase 2]
This Phase 2 trial assessed rituximab in combination with chemotherapy for patients with previously untreated mantle cell lymphoma. Results …
-
CLINICAL_TRIALS trial_result · 2025-07-22Clinical Trial Update: Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) [Phase 3]
Phase 3 trial assessing ibrutinib in combination with venetoclax for mantle cell lymphoma has completed, and its results have been posted.
-
CLINICAL_TRIALS trial_result · 2025-07-16Clinical Trial Update: Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma
A completed follow-up study evaluating a CD19 CAR-T cell therapy engineered to express IL7 and CCL19 for relapsed or refractory B-cell lymph…
-
CLINICAL_TRIALS trial_result · 2025-07-10Clinical Trial Update: Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. [Phase 3]
A phase 3 trial comparing lenalidomide plus rituximab followed by lenalidomide versus rituximab maintenance in relapsed/refractory follicula…
-
CLINICAL_TRIALS trial_result · 2025-07-04Clinical Trial Update: UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep [Phase 2]
Phase 2 clinical trial evaluating non-myeloablative preparative regimens followed by umbilical cord blood transplantation for various hemato…
-
CLINICAL_TRIALS trial_result · 2025-06-18Clinical Trial Update: A Phase 1 Study of ADI-001 in B Cell Malignancies [Phase 1]
The Phase 1 study of ADI-001 in B cell malignancies has been terminated.